http://www.biospace.comBioSpace RSS GeneratorWed, 19 Jun 2013 09:10:20 GMT20http://rss.biospace.com/images/BSPLogo.gifhttp://www.BioSpace.com/news.aspx?SectionId=1Copyright (C) 2011http://medcitynews.com/2013/06/success-with-an-angel-syndicate-how-one-pharma-startup-raised-16m-without-vcs/Staying up-to-date has never been simpler. Sign up for the <a href"http://www.biospace.com/enewsletter.aspx?typeseo-article&sourcenews-signup">free GenePool newsletter</a> today!<br><br>Savara Pharmaceuticals needed several million dollars to take its inhalable drug for troublesome infections in cystic fibrosis patients through Phase 2 clinical trials. So CEO Rob Neville, naturally, began talking...Tue, 18 Jun 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=299892&full=1Staying up-to-date has never been simpler. Sign up for the <a href"http://www.biospace.com/enewsletter.aspx?typeseo-article&sourcenews-signup">free GenePool newsletter</a> today!<br><br><font size"3"><b>PRISM Pharma Closes $15 million Series C Financing to Advance PRI-724 into Non-oncology Indications</font></b><br><br>YOKOHAMA, Japan</span>, <span class"xn-chron">June 13, 2013</span...Thu, 13 Jun 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=299659&full=1Staying up-to-date has never been simpler. Sign up for the <a href"http://www.biospace.com/enewsletter.aspx?typeseo-article&sourcenews-signup">free GenePool newsletter</a> today!<br><br>Glasgow, June 9 2013: Collbio, a new company set up in March this year by leading life science financiers Diagnostic Capital Ltd, together with former senior management team members Stewart White and Ross Andrews...Tue, 11 Jun 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=299118&full=1Staying up-to-date has never been simpler. Sign up for the <a href"http://www.biospace.com/enewsletter.aspx?typeseo-article&sourcenews-signup">free GenePool newsletter</a> today!<br><br>(Oslo, June 6, 2013) Cancer vaccine specialist Targovax today announced that it has raised a total of $3.6 million to accelerate development of its RAS mutation-targeted therapeutic cancer vaccine pipeline...Wed, 05 Jun 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=298286&full=1Staying up-to-date has never been simpler. Sign up for the <a href"http://www.biospace.com/enewsletter.aspx?typeseo-article&sourcenews-signup">free GenePool newsletter</a> today!<br><br>GREENSBORO, North Carolina May 29, 2013 -- Arcato Laboratories, Inc., an emerging oral health company, announced today that it has executed a term sheet with Piedmont Angel Network (PAN), who will lead the...Wed, 29 May 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=297997&full=1Staying up-to-date has never been simpler. Sign up for the <a href"http://www.biospace.com/enewsletter.aspx?typeseo-article&sourcenews-signup">free GenePool newsletter</a> today!<br><br><font size"3"><b>Cobra Biologics and Recopharma Enter agreement to utilise Cobras Cell Line Development Service- MaxXpress</font></b><br><br>28 May 2013 -- DUBLIN, IRELAND: May 28th 2013, TRINO THERAPEUTICS...Tue, 28 May 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=296614&full=1Staying up-to-date has never been simpler. Sign up for the <a href"http://www.biospace.com/enewsletter.aspx?typeseo-article&sourcenews-signup">free GenePool newsletter</a> today!<br><br> <div class"xn-content"><p><span class"xn-location">DOYLESTOWN, Pa.</span>, <span class"xn-chron">May 14, 2013</span> /PRNewswire/ -- Callidus Biopharma, Inc., a development-stage biotechnology company...Tue, 14 May 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=295714&full=1Staying up-to-date has never been simpler. Sign up for the <a href"http://www.biospace.com/enewsletter.aspx?typeseo-article&sourcenews-signup">free GenePool newsletter</a> today!<br><br>SAN DIEGO</span>, <span class"xn-chron">May 8, 2013</span> /PRNewswire/ -- <a href"http://www.lumenapharma.com/" target"_blank">Lumena Pharmaceuticals</a>, a company developing oral therapeutics for rare...Wed, 08 May 2013 12:00:00 AM GMThttp://www.chinabiotoday.com/articles/20130502_2Staying up-to-date has never been simpler. Sign up for the <a href"http://www.biospace.com/enewsletter.aspx?typeseo-article&sourcenews-signup">free GenePool newsletter</a> today!<br><br>by Richard Daverman, PhD</p><p>May 2, 2013 -- Zhejiang Huahai Pharma will offer 63.3 million shares at a price of 12.25 RMB each, raising 775 million RMB ($126 million) in a secondary offering. It...Fri, 03 May 2013 12:00:00 AM GMThttp://www.bizjournals.com/triangle/news/2013/04/29/raleigh-startup-scioderm-nets-9m.html?ana=otjStaying up-to-date has never been simpler. Sign up for the <a href"http://www.biospace.com/enewsletter.aspx?typeseo-article&sourcenews-signup">free GenePool newsletter</a> today!<br><br>Raleigh startup Scioderm has nabbed $9 million in equity in a recent fundraise. A newly released securities filing shows that the team still has $7 million to go in the round. The dermatological research...Tue, 30 Apr 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=294189&full=1Staying up-to-date has never been simpler. Sign up for the <a href"http://www.biospace.com/enewsletter.aspx?typeseo-article&sourcenews-signup">free GenePool newsletter</a> today!<br><br>RESEARCH TRIANGLE PARK, N.C. and SAN DIEGO, April 23, 2013 (GLOBE NEWSWIRE) -- Tranzyme Pharma (TZYM) ("Tranzyme"), a biopharmaceutical company focused on discovering, developing and commercializing novel...Wed, 24 Apr 2013 12:00:00 AM GMThttp://www.chinabiotoday.com/articles/20130422_1by Richard Daverman, PhD</p><p>April 22, 2013 -- Syros Pharmaceuticals, a Boston area startup, raised $30 million to develop treatments for cancer and other diseases by controlling the switches that regulate gene expression. The WuXi PharmaTech Corporate Venture Fund participated in the funding, which was led by ARCH Venture Partners and Flagship Ventures. More details....</p><p>Stock Symbol...Tue, 23 Apr 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=293627&full=1Lrrach, Germany and Saint Louis, France The creation of Allecra Therapeutics, a new company joining the established European BioValley Life Sciences cluster, was announced today. Allecra is a biopharmaceutical company dedicated to the development of novel antibiotics to combat multi drug-resistant bacterial infections. Allecras 15 million Series A financing round was co-led by Edmond de Rothschild...Thu, 18 Apr 2013 12:00:00 AM GMThttp://www.businesswire.com/portal/site/biospace/index.jsp?ndmViewId=news_view&newsId=20130416005676&newsLang=enSEATTLE--(BUSINESS WIRE)--BEATBio, a Seattle, Wash.-based biotechnology company focused on the development of a novel gene therapy to improve cardiac performance in the setting of heart failure, today announced the closing of a $2.5 million seed stage investment with funding provided by CET Capital Partners. Participating investors include the W Fund. The proceeds will be used to move BEATBios lead...Tue, 16 Apr 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=293289&full=1Copenhagen, April 15th, 2013 -- Avilex Pharma ApS today announced the raising of seed funding from Novo Seeds, the earlystage financing arm of Novo A/S to support the development of novel dimeric ligandstargeting PDZ domains. Based on the work of Professor Kristian Strmgaard, Dr. AndersBach and their team at the University of Copenhagen, the lead compounds provideunprecedented potency against...Mon, 15 Apr 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=293133&full=1WATERTOWN, Mass.--(BUSINESS WIRE)-- Syros Pharmaceuticals, a newly launched company harnessing breakthroughs in gene control to revolutionize the treatment of cancer and other diseases, today announced that it has completed a $30 million Series A financing led by company Co-founders ARCH Venture Partners and Flagship Ventures. Syros will use the capital to accelerate the discovery and development of...Fri, 12 Apr 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=293013&full=1CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cydan, LLC, an orphan drug accelerator that identifies and de-risks programs with therapeutic and commercial potential, today announced its launch with $16 million in financing led by New Enterprise Associates (NEA) and Pfizer Venture Investments, with participation from Alexandria Real Estate Equities, Inc. The accelerator will focus on identifying promising assets...Thu, 11 Apr 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=293019&full=1HEIDELBERG, Germany--(BUSINESS WIRE)--Novaliq GmbH, a drug delivery company with a focus on the efficacious topical application of poorly soluble drugs, today announced the successful completion of a fifth round of financing of 13.9m ($18.1m). Since 2007, the company has raised 27.1m ($35.2m). </p><p>Financing was again secured exclusively from the investment company of SAP, co-founder Dietmar...Thu, 11 Apr 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=293017&full=1RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--AgBiome LLC, a private company developing novel agricultural products to improve crop productivity, today announced that it has secured $14.5 million in Series A financing that will further advance the companys research and development programs, and support the launch of the companys first products. Polaris Partners led the round and was joined by ARCH...Thu, 11 Apr 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=292597&full=1PARIS, April 8, 2013 -- /PRNewswire/ -- GenSight Biologics, a biopharmaceutical company focused on the development of ophthalmic therapeutics using gene therapy, announced today the closing of a 32 million Series A financing.</p><p>The financing was co-led by Novartis Venture Fund, Abingworth LLP, Versant Ventures and Index Ventures. GenSight will use the funds to develop a gene replacement therapy...Mon, 08 Apr 2013 12:00:00 AM GMThttp://medcitynews.com/2013/04/cardiac-device-startup-gets-2-5m-investment-but-stays-quiet-on-technology-for-heart-disease/New medical device company Adagio Medical might be laying low, but its executives revealed in a securities filing this week that the California startup has secured a $2.5 million investment. Theres not much publicly available information about what the Laguna Hills-based company is working on, aside from the fact that its focused on finding innovative ways to treat cardiovascular disease in order...Fri, 05 Apr 2013 12:00:00 AM GMThttp://www.sfgate.com/business/prweb/article/Bina-Nets-6-25-Million-Series-B-Financing-Led-by-4385978.phpRedwood City, CA (PRWEB) March 26, 2013 -- Bina Technologies, the genomic big data science platform accelerating personalized medicine, today announced that it has closed a $6.25 million round of Series B financing led by Sierra Ventures. Founded in 2011 by experts in complex, large-scale genomics, big data and high-performance computing, Binas mission is to process and mine vast volumes of genomic...Wed, 27 Mar 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=291395&full=1London, UK, 25 March 2013: SEEK, a privately-owned UK drug discovery group, announces today that its first spin-out, infirst HEALTHCARE, a consumer healthcare company commercialising unique, fast-to-market medicines, has successfully raised 25 million of new funds. The funding, from Invesco Asset Management managed funds, will be used for the launch of infirsts medicines into the US$ 20 billion cough...Mon, 25 Mar 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=291393&full=1DOYLESTOWN, Pa.</span>, <span class"xn-chron">March 25, 2013</span> /PRNewswire/ -- <a href"http://www.noviratherapeutics.com/" target"_blank">Novira Therapeutics, Inc.</a> today announced the completion of its Series A financing after securing <span class"xn-money">$7.5 million</span> from new investor Versant Ventures. This brings the total raised from all investors in the round to <span class...Mon, 25 Mar 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=291420&full=1SEATTLE--(BUSINESS WIRE)-- Theraclone Sciences, Inc., a therapeutic antibody discovery and development company, today announced a $14 million financing. $8 million in equity is committed from existing investors ARCH Venture Partners, Canaan Partners, MPM Capital, Healthcare Ventures, Alexandria Real Estate Equities, Amgen Ventures, Versant Ventures and Zenyaku Kogyo in a Series B Extension, bringing...Mon, 25 Mar 2013 12:00:00 AM GMThttp://www.bizjournals.com/sanjose/news/2013/03/21/schizophrenia-drug-startup-reviva.html?ana=otjReviva Pharmaceuticals, which is developing a drug to treat schizophrenia, disclosed on Thursday that it has raised $12 million in debt and equity funding. The San Jose company led by CEO Laxminarayan Bhat didn't disclose its funders but said the money came from 82 people. Bhat is the only person listed on the Securities & Exchange Commission filing about the funding.Fri, 22 Mar 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=288631&full=1MIAMI--(BUSINESS WIRE)-- Brickell Biotech, Inc. (Brickell), a development-stage pharmaceutical company focused on the development of innovative drug therapies for the treatment of skin diseases, today announced a $7 million Series B financing round. Brickells current pipeline includes new chemical entities in dermatology for indications including acne, atopic dermatitis, and hyperhidrosis.</p...Tue, 26 Feb 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=287670&full=1CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Third Rock Ventures, LLC today announced the formation of Jounce Therapeutics, Inc. with a $47 million Series A financing of the company. Jounce is focused on the discovery and development of first-in-class cancer immunotherapies designed to harness the patients immune system to seek out and attack cancerous cells and tumors. This transformational approach, as compared...Fri, 15 Feb 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=287752&full=1Sydney, Australia, 14 February 2013 - Helmedix Pty Ltd, an early stage biopharmaceutical company developing novel therapies for autoimmune and inflammatory diseases such as rheumatoid arthritis, colitis, psoriasis and multiple sclerosis, was launched today with start-up financing from Australias Medical Research Commercialisation Fund (MRCF).</p><p>Based on intellectual property from the University...Thu, 14 Feb 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=287760&full=1Cambridge, UK, February 14, 2013 / B3C newswire / - Domainex Ltd., a UK-based drug discovery company, has announced an investment round to raise 1.5m of capital. This round had a successful first close in December 2012, with investments made by Longbow Capital, Bury Fitzwilliam-Lay and Partners and University College London Business (UCLB), who together represent the interests of more than half of...Thu, 14 Feb 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=285961&full=1January 29, 2013 -- BONE THERAPEUTICS, the leading international biopharmaceutical company focused on innovative cell therapy products for the treatment of bone diseases, announces today that it has successfully closed a Series D funding round, raising 7.7 million from current investors and the Walloon Region.</p><p>The funds raised will be used to further accelerate the development of Bone Therapeutics...Tue, 29 Jan 2013 12:00:00 AM GMThttp://www.tennessean.com/article/20130124/NEWS07/301240121/Meningitis-outbreak-Judge-OKs-possible-freeze-NECC-owners-assetsAttorneys representing creditors of New England Compounding Pharmacy, a bankrupt Massachusetts custom drug maker tied to a fatal meningitis outbreak, are seeking to claw back more than $21 million, after revelations that owners pulled out funds in the year before the firm sought Chapter 11 protection. In a document filed Tuesday, the creditors asked the court for standing to prosecute claims against...Fri, 25 Jan 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=285403&full=1Montreal, Canada, January 22, 2013 / B3C newswire / - TVM Life Science Ventures VII today announced an investment into Kaneq Bioscience Ltd. based in Montreal, Quebec. This company is a spin out of Kaneq Pharma Inc., a biotechnology company developing early stage compounds for metabolic diseases and cancer. Kaneq Bioscience Ltd. was specifically created to develop a protein tyrosine phosphatase1B ...Tue, 22 Jan 2013 12:00:00 AM GMThttp://www.bizjournals.com/tampabay/blog/morning-edition/2013/01/keyview-labs-raises-114m.html?ana=otjBallast Point Ventures and other investors have pumped $11.4 million into KeyView Labs Inc. KeyView, a consumer health products firm based in Sarasota, will use the funding to support the acquisition of Brain Research Labs and for growth capital, a statement from Ballast Point said. KeyView raised a total of $11.4 million from 10 investors in an equity and debt offering, according to a filing with...Wed, 16 Jan 2013 12:00:00 AM GMThttp://medcitynews.com/2013/01/investors-have-put-15-5m-behind-this-cancer-drug-startup-reviving-a-shelved-hsp90-inhibitor/A cancer pharmaceutical startup called Esanex generated lots of reader interest back in May when it began raising a $15 million round. The latest U.S. Security and Exchange Commission filing from Esanex (in December) shows that the round was completed with $15.5 million, and today, the Indiana Seed Investment Fund II said it participated in Esanexs series A with a $500,000 investment. Managed by life...Fri, 11 Jan 2013 12:00:00 AM GMThttp://www.businesswire.com/portal/site/biospace/index.jsp?ndmViewId=news_view&newsId=20130109006580&newsLang=enST. LOUIS--(BUSINESS WIRE)--NewLeaf Symbiotics, Inc. today announced the completion of a $7.0 million round of financing. Investors in the syndicate include Rockport Capital, Open Prairie Ventures, Pangaea Ventures, and several individuals. NewLeaf Symbiotics is an agricultural biotech firm that is commercializing a family of beneficial bacteria known as PPFMs (Pink Pigmented Facultative Methylotrophs...Thu, 10 Jan 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=283904&full=1Leiden, the Netherlands, January 7, 2013 ISA Pharmaceuticals B.V., a clinical-stage biopharmaceutical company focusing on rationally designed therapeutic vaccines against cancer and persistent viral infections, has today announced that it has raised EUR 8 million in a follow-on round from its existing investor base.</p><p>The proceeds will be used to fund a randomized Phase II clinical trial...Mon, 07 Jan 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=283477&full=1SAN FRANCISCO</span>, <span class"xn-chron">Jan. 3, 2013</span> /PRNewswire/ -- Labrys Biologics Inc., a company focused on treatments for chronic migraine, today announced the completion of a <span class"xn-money">$31 Million</span> Series A financing from four leading venture capital firms, venBio, Canaan Partners, InterWest Partners, and Sofinnova Ventures. With the close of the financing, Labrys...Thu, 03 Jan 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=283494&full=1DALLAS</span>, <span class"xn-chron">Jan. 3, 2013</span> /PRNewswire/ -- Gradalis, Inc. today announced that is has closed a <span class"xn-money">$24 million</span> Series B round of financing. Gradalis will use the funding to advance its autologous vaccine platform, FANG, through late-stage clinical trials and expand manufacturing capabilities to accommodate commercial launch of FANG. In addition...Thu, 03 Jan 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=282602&full=1NEW HAVEN, Conn.--(BUSINESS WIRE)-- Trevi Therapeutics, Inc. (Trevi) today announced the closing of a $10 million Series A financing to advance the clinical development of T111 in the lead indication of uremic pruritus. The Series A investment was completed with TPG Biotech, the life science venture investment arm of TPG which had previously made a seed investment in the Company.</p><p>With the...Tue, 18 Dec 2012 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=282433&full=1SAN MATEO, Calif.</span>, <span class"xn-chron">Dec. 17, 2012</span> /PRNewswire/ -- Allakos Inc. announced today that it has completed a <span class"xn-money">$32 million</span> Series A preferred stock financing led by <a href"http://www.novo.dk/" target"_blank">Novo Ventures</a> with participation from <a href"http://altapartners.com/" target"_blank">Alta Partners</a>, <a href"http://www...Mon, 17 Dec 2012 12:00:00 AM GMThttp://www.smartplanet.com/blog/bulletin/biotech-startup-transcriptic-raises-12m-cloud-automation-for-the-lab/8025Startup biotech company Transcriptic has raised $1.2 million in a seed funding round from a wide group of investors led by Google Ventures and FF Angel (Founders Funds seed stage arm), and private investors Mark Cuban and Naval Ravikant. Notably, more than 60 accredited investors contributed $150,000 through a partnership between investment platforms AngelList and SecondMarket, which Transcriptic...Fri, 14 Dec 2012 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=281418&full=1CAMBRIDGE, Mass.</span>, <span class"xn-chron">Dec. 6, 2012</span> /PRNewswire/ -- Moderna Therapeutics announced today that it has closed more than <span class"xn-money">$40 million</span> in financing to date, led by Flagship Ventures and private investors, which will be used to advance multiple programs toward clinical stage development. Moderna is pioneering messenger RNA Therapeutics, a novel...Thu, 06 Dec 2012 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=281419&full=1SAN DIEGO</span>, <span class"xn-chron">Dec. 6, 2012</span> /PRNewswire/ -- Avelas Biosciences today announced that it has closed a <span class"xn-money">$7.65 million</span> Series A round of financing. Avelas will use the funding to advance the Avelas Cancer Illuminator (ACI) towards clinical studies for the visualization of cancerous lymph nodes in breast cancer patients. The company is funded...Thu, 06 Dec 2012 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=280434&full=1<div id"releaseBody"><p>BUFFALO, NY--(Marketwire - November 20, 2012) - <b>QuaDPharma, LLC </b>(Clarence, NY) (<a href"http://www.qdpharma.com/">www.qdpharma.com</a>) has completed a $1 million financing investment from Rand Capital SBIC, Inc. (Buffalo, NY) (<a href"http://www.randcapital.com/">www.randcapital.com</a>) (NASDAQ: <a href"http://www.marketwire.com/mw/stock.jsp?TickerRAND">RAND...Wed, 21 Nov 2012 12:00:00 AM GMThttp://www.chinabiotoday.com/articles/20121116Suzhou, China, November 16, 2012 / B3C newswire / - Innovent Biologics, Inc., a company dedicated to the development and manufacturing of monoclonal antibodies to be marketed in the rapidly growing China market and elsewhere around the world, has raised $25 Million in a Series B financing to put toward the continued expansion of its pipeline and manufacturing capabilities. The money comes from Lilly...Fri, 16 Nov 2012 12:00:00 AM GMThttp://www.businesswire.com/portal/site/biospace/index.jsp?ndmViewId=news_view&newsId=20121101006819&newsLang=enMALVERN, Pa.--(BUSINESS WIRE)--Benten BioServices, Inc., (www.BentenBio.com), a privately-held Contract Services Organization headquartered in Malvern, PA, today announced the completion last month of $1.1 million in new convertible debt financing. In August, Benten raised $2.94 million in a Series A Preferred Stock funding, bringing the total amount Benten has raised in 2012 to $4.0 million. Investors...Fri, 02 Nov 2012 12:00:00 AM GMThttp://www.bizjournals.com/dallas/news/2012/10/23/zs-pharma-lands-46-million-for-kidney.html?ana=otjrssDallas Business Journal by Bill Hethcock, Staff Writer </p><p>Specialty pharmaceutical company ZS Pharma Inc. has raised $46 million to advance development of ZS-9, a crystal form of zirconium silicate, designed to treat patients with kidney and liver disease.</p><p>The funding will allow the privately held Fort Worth company to proceed with trials for ZS-9 as it prepares for commercialization...Wed, 24 Oct 2012 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=277030&full=1MALVERN, Pa.--(BUSINESS WIRE)-- Aclaris Therapeutics, Inc., a privately held specialty pharmaceutical company dedicated to developing dermatological therapeutics, announced today that it has secured $21 million in Series A financing. The Series A was led by Vivo Ventures and Fidelity Biosciences with participation from Sofinnova Ventures. Proceeds from the financing will be used to fund the development...Wed, 24 Oct 2012 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=276870&full=1REHOVOTH, Israel--(BUSINESS WIRE)-- Pharma Two B Ltd., a privately held company focused on developing Fixed-Dose-Combinations (FDCs) of two or more drugs with complementary and synergistic effects, announced that it has completed its second round of financing and has raised $8 million.</p><p>Financing will be used to continue the development of the company's Fixed-Dose-Combination product for the...Tue, 23 Oct 2012 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=276443&full=1CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Neurovance, Inc. today announced that it has closed a $7 million series A1 round led by existing investor Novartis Venture Fund to further advance development of EB-1020. Neurovance is a spinout of Euthymics Bioscience, Inc., its affiliated company under the same ownership. Neurovance was created to focus on development of EB-1020 for adult attention deficit hyperactivity...Thu, 18 Oct 2012 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=275992&full=1<div id"releaseBody"><p>SUNRISE, FL--(Marketwire - October 15, 2012) - NorthStar Biotech, LLC, a consortium of Bioheart, Inc. (OTCQB: <a href"http://www.marketwire.com/mw/stock.jsp?TickerBHRT">BHRT</a>) Directors and Shareholders, led by Managing Director Chuck Hart, has launched a series A private placement financing round and intends to raise a maximum capital of $20 million in exchange for...Mon, 15 Oct 2012 12:00:00 AM GMThttp://www.bizjournals.com/twincities/news/2012/09/19/healthsense-gets-funding-from-merck.html?ana=otjMinneapolis / St. Paul Business Journal by Ed Stych, Web Producer </p><p>Healthsense Inc., a Twin Cities company that markets health-monitoring systems for seniors, said Wednesday it has received $7 million in financing from Merck Global Health Innovation Fund and others.</p><p>Mendota Heights-based Healthsense said in a news release that Fallon Community Health Plan was another one of the...Thu, 20 Sep 2012 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=273114&full=1REDWOOD CITY, Calif., Sept. 17, 2012 (GLOBE NEWSWIRE) -- Station X Inc., a company dedicated to simplifying the analysis and visualization of genome-scale data in clinical and research settings, today announced the closing of a second round of equity financing led by Runa Capital, an international venture capital firm. The $5 million round also included follow-on commitments from existing investors...Mon, 17 Sep 2012 12:00:00 AM GMThttp://www.businesswire.com/portal/site/biospace/index.jsp?ndmViewId=news_view&newsId=20120917005960&newsLang=enST. LOUIS--(BUSINESS WIRE)--Confluence Life Sciences, Inc., a biotechnology company focused on the rapid discovery and development of kinase inhibitors to treat cancer and inflammatory disease, today announced a $4 million Series A venture capital financing. Proceeds from the financing will enable Confluence to advance its product candidates and leverage its proprietary technology platform to discover...Mon, 17 Sep 2012 12:00:00 AM GMThttp://www.bizjournals.com/philadelphia/news/2012/09/12/malvern-biopharma-raises-21m-in-stock.html?ana=otjPhiladelphia Business Journal by John George, Senior Reporter</p><p>Aclaris Therapeutics raised $20.9 million in private stock sale this week, according to documents filed with the Securities and Exchange Commission.</p><p>The biopharmaceutical company, based in Malvern, Pa., is specializing in developing new treatments for skin disorders.</p><p>Philadelphia law firm Duane Morris served...Thu, 13 Sep 2012 12:00:00 AM GMThttp://www.xconomy.com/boston/2012/09/10/annovation-adds-8m-to-develop-safer-more-precise-anesthesia/Annovation BioPharma is announcing today that it has raised $8 million in a Series A funding to put toward the development of new therapies for anesthesia and critical care. The money comes from return seed investors, Cambridge, MA-based Atlas Venture and Partners Innovation Fund, as well as new strategic investor The Medicines Company (NASDAQ: MDCO). The round could hit a total of $11 million through...Mon, 10 Sep 2012 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=271913&full=1CLEVELAND</span>, <span class"xn-chron">Sept. 5, 2012</span> /PRNewswire/ -- BioMotiv today announced that it has secured <span class"xn-money">$21 million</span> in financing from its founding investors, University Hospitals and the Harrington Family. </p><p>"BioMotiv is a new model for accelerating breakthrough discoveries into medicines and aligning capital and collaborations to develop a portfolio...Wed, 05 Sep 2012 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=271667&full=1PARIS THERAVECTYS, a biotechnology company that is developing a new generation of vaccines based on lentiviral vector technology (*), announced today that it has secured 7.48 million euros as of the end of H1 2012. These funds, raised exclusively from private investors, will enable THERAVECTYS to pursue the development of a new generation of vaccines, with an anti-HIV therapeutic vaccine as first...Tue, 04 Sep 2012 12:00:00 AM GMThttp://www.pehub.com/164362/aerpio-therapeutics-closes-27m-series-a/CINCINNATI--(BUSINESS WIRE)-- Aerpio Therapeutics, a clinical-stage biopharmaceutical company focused on advancing innovative therapies for vascular diseases, today announced that is has closed a $27 million Series A financing. The round was led by Novartis BioVentures and joined by Venture Investors LLC, Triathlon Medical Ventures, Kearny Venture Partners, Athenian Venture Partners and AgeChem Venture...Thu, 30 Aug 2012 12:00:00 AM GMThttp://www.bizjournals.com/philadelphia/news/2012/08/23/novira-raises-11m-in-stock-sale.html?ana=otjrssRADNOR, Pa.</span>, <span class"xn-chron">Aug. 24, 2012</span> /PRNewswire/ -- Novira Therapeutics Inc. today announced it has secured <span class"xn-money">$23 million</span> in Series A financing to support the development of its capsid-targeting antivirals for the treatment of chronic hepatitis B (HBV) and HIV infections. </p><p>The financing was co-led by new investors <span class"xn-chron...Fri, 24 Aug 2012 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=268908&full=1ANN ARBOR, Mich., Aug 03, 2012 (BUSINESS WIRE) -- Atterocor, Inc., a company developing an innovative therapy for adrenal cancer, today announced a $16 million Series A venture capital financing. Frazier Healthcare and 5AM Ventures led the round and proceeds from the financing will support Atterocor's accelerated development of its lead program. </p><p>"We are excited to launch Atterocor with this...Fri, 03 Aug 2012 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=268484&full=1Boston, MA Pingup South Boston-based Pingup, developer of consumer-to-business text service, announced today the completion of their $1 million seed financing round with major participation from Venture Capital firm, Avalon Ventures.Avalon Ventures, who operates from offices in Cambridge, MA and La Jolla, CA, is an early stage venture capital fund focused on information technology and life sciences...Tue, 31 Jul 2012 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=267903&full=1PARAMUS, N.J.</span>, <span class"xn-chron">July 26, 2012</span> /PRNewswire/ -- Mycell Technologies LLC, a leading intellectual property and investment holding company, specializing in the development of proprietary liquid formulations of stable, highly concentrated omega-3s for use in food, beverage, medical and nutritional products, announced today the closing of an institutional non-controlling...Thu, 26 Jul 2012 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=267653&full=1<div class"xn-content"><p><span class"xn-location">BLUE BELL, Pa.</span>, <span class"xn-chron">July 24, 2012</span> /PRNewswire/ -- Relmada Therapeutics, a clinical-stage company developing novel therapies for the treatment of chronic pain today announced the initial closing of <span class"xn-money">$3 million</span> in gross proceeds in a Series A financing for which Laidlaw &amp; Company (UK...Tue, 24 Jul 2012 12:00:00 AM GMThttp://wraltechwire.com/business/tech_wire/news/blogpost/11311290/If sexual statistics are to be believed, roughly 43 percent of American women suffer from some form of female sexual dysfunction. But pharmaceutical companies to date have only commercialized male sex drugs. Pfizers (NYSE: PFE) Viagra in 1998 famously became the first erectile dysfunction drug targeting men looking to revive their sex lives. It spurred other firms to develop libido-enhancing drugs...Mon, 16 Jul 2012 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=266795&full=1<div id"releaseBody"><p>STONY BROOK, NY--(Marketwire - July 16, 2012) - Coferon Inc., a privately held, New York-based biotechnology company, today announced that it has closed on a $12 million Series B financing round led by a trio of new venture investors: Hatteras Venture Partners of Durham, N.C.; MedImmune Ventures of Gaithersburg, MD (the corporate venture arm of AstraZeneca Ltd); and...Mon, 16 Jul 2012 12:00:00 AM GMThttp://www.businesswire.com/portal/site/biospace/index.jsp?ndmViewId=news_view&newsId=20120712005732&newsLang=enRALEIGH, N.C.--(BUSINESS WIRE)--Rex Health Ventures, one of the nations only venture-capital funds managed by a community, nonprofit hospital, is pleased to announce its first investment, a $500,000 equity placement in Aerial BioPharma. Thu, 12 Jul 2012 12:00:00 AM GMThttp://www.businesswire.com/portal/site/biospace/index.jsp?ndmViewId=news_view&newsId=20120628005294&newsLang=enSAN FRANCISCO--(BUSINESS WIRE)--Gemmus Pharma Inc. announced today that it has closed on a Series A funding. Gemmus is a privately held biotechnology company developing an improved host-targeted treatment for influenza. The funding will be used to prepare for an IND filing of a candidate therapy that reduces symptoms during influenza infections by modulating the bodys own beneficial immune response...Thu, 28 Jun 2012 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=264428&full=1Nijmegen, The Netherlands, June 19, 2012 Xenikos BV (Xenikos) has completed a EUR 3.6 million Series A financing round with strategic partner Sanquin Blood Supply Foundation (Sanquin), Participatiemaatschappij Oost Nederland N.V., and Innovation & Investment Fund Gelderland B.V. In addition, Xenikos has secured a EUR 1.9 million Innovation Credit granted by Agentschap NL, an agency...Tue, 19 Jun 2012 12:00:00 AM GMThttp://www.xconomy.com/san-francisco/2012/06/14/global-blood-therapeutics-third-rocks-first-west-coast-startup-gets-41m/San Francisco Business Times by Ron Leuty, Reporter </p><p>Drug developers talk a lot about large patient populations, unmet medical needs and a clear path to approval. Yet sickle cell disease, one of the knottiest diseases meeting all those criteria, has gone years without a breakthrough commercial treatment.</p><p>That might prove an advantage for Global Blood Therapeutics Inc., the...Thu, 14 Jun 2012 12:00:00 AM GMThttp://bankruptcynews.dowjones.com/Article?an=DJFVW00020120611e86brw7r6&ReturnUrl=http%3a%2f%2fbankruptcynews.dowjones.com%3a80%2fArticle%3fan%3dDJFVW00020120611e86brw7r6A new bioscience venture firm seeks $200 million to invest in a state with plenty of sun and science but not much start-up capital. The firm, Select BioVentures, formed late last summer and began raising Select BioVenture Partners LP early this year, according to Dale A. Barnstable, a managing member of the Palm Beach, Fla., firm.Wed, 13 Jun 2012 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=262574&full=1Lyon, France, June 4, 2012 - Alize Pharma, a group of companies developing drugs for the treatment of metabolic diseases and cancer, announces today that it has completed a funding round of EUR 3.3 million. The funds will allow to take AZP-531, its UAG (UnAcylated Ghrelin) analog, into Phase I clinical trials.</p><p>Alize Pharma will carry out the first (Phase I) clinical trial of AZP-531 in healthy...Mon, 04 Jun 2012 12:00:00 AM GMThttp://www.richmondbizsense.com/2012/05/30/a-shot-of-accelerant/RICHMOND, Va.--(BUSINESS WIRE)-- Intelliject, Inc., a specialty pharmaceutical company pioneering the next generation of drug/device combination products, today announced that it has entered into a $15 million debt facility with Hercules Technology Growth Capital, Inc. (HTGC) to enable Intelliject to accelerate the development of key pipeline products. Hercules is a leading specialty finance company...Wed, 30 May 2012 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=261173&full=1Zurex Pharma Inc., a Middleton, Wisc.-based life sciences company, has raised $6.2 million in Series A financing. Baird Venture Partners and the State of Wisconsin Investment Board led the round, with participation from Wisconsin Investment Partners, Peak Ridge Capital and unnamed individuals. The company will use the money to develop and commercialize its products, which are designed to prevent healthcare...Tue, 22 May 2012 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=260535&full=1Cambridge, MA, May 16, 2012 Ra Pharmaceuticals today announced it is pursuing hereditary angioedema (HAE) as a lead program, leveraging the Companys proprietary Cyclomimetic drug discovery and development platform. HAE is a rare, but serious and often fatal disorder of the innate immune system that causes intermittent attacks characterized by swelling and pain of the face, airways and intestinal...Wed, 16 May 2012 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=260584&full=1NEW ORLEANS</span>, <span class"xn-chron">May 16, 2012</span> /PRNewswire/ -- NuMe Health LLC, a biotechnology company developing evidence-based cobiotic<span></span> products that modify the bacteria that live in the gastrointestinal (GI) tract to support health and well-being, today announced that it has closed a <span class"xn-money">$1.5 million</span> Series A financing. NuMe also announced...Wed, 16 May 2012 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=259071&full=1NEW YORK--(BUSINESS WIRE)-- Retrophin, LLC, a privately-held New York-based, biotechnology company focused on discovering and developing treatments for rare and life-threatening diseases, today announced completion of its Series A financing. The $4 million round was led by MSMB Capital. </p><p>The company intends to invest the proceeds from the Series A financing to advance its pipeline of novel...Mon, 07 May 2012 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=257921&full=1SOLANA BEACH, Calif.</span>, <span class"xn-chron">April 27, 2012</span> /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (OTC Markets: IMMY) announced that it has closed a <span class"xn-money">$7.95M</span> private placement of stock and warrants and is providing an update to shareholders and the market.</p><p>Imprimis Pharmaceuticals, Inc. CEO <span class"xn-person">Mark L. Baum</span> stated...Fri, 27 Apr 2012 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=257245&full=1<div class"xn-content"><p><span class"xn-location">NEW YORK</span>, <span class"xn-chron">April 23, 2012</span> /PRNewswire/ -- Oligomerix, Inc., a privately held company pioneering the development of disease modifying therapeutics for Alzheimer's disease and related neurodegenerative disorders, announced today the completion of approximately <span class"xn-money">$2 million</span> in Series A...Mon, 23 Apr 2012 12:00:00 AM GMT